Qilu pharmaceutical exports $51 million in January!

Qilu Pharmaceutical Group yesterday announced that as of January 28, Qilu pharmaceutical had completed a total of $51 million in product exports in January 2019, maintaining a good development trend since last year In 2018, Qilu pharmaceutical realized exports of $615 million, with significant growth in the regulatory markets of the United States and Japan, of which exports to the United States increased by 126% and exports to Japan increased by 90% As one of the main export forces of Qilu Pharmaceutical Group, Qilu Tianhe Huishi Pharmaceutical Co., Ltd made a breakthrough in "zero" export of preparations to the United States in December 2018, becoming a new highlight of the group's export It is worth mentioning that in the past two months, the total export volume of Tianhe Huishi has increased by 11% The export volume of Europe, America and Japan accounts for nearly 70% of the total export volume, and the export geographical structure is good In terms of export structure, the export growth of high-end pharmaceutical products to countries with regulatory market is obvious; in terms of country statistics, the products are mainly exported to the United States, Japan, the European Union (including Germany, Austria, Italy, Greece, Cyprus) and other countries and regions.